Amgen recalls anemia drugs due to glass flakes

Sep 24, 2010

(AP) -- Amgen Inc. is recalling some lots of its Epogen and Procrit anemia treatments because they may contain glass flakes.

The Thousand Oaks, Calif., biotechnology company says the flakes are barely visible in most cases, and they have fielded no complaints or reports about problems that can be directly tied to them.

Amgen says the flakes are caused by the interaction of the drug with glass vials over the product's shelf life.

The affected lot numbers and expiration dates can be found on Web sites for the products.

Epogen treats in patients with chronic renal failure who are on dialysis. Procrit also treats it for on and some HIV-infected patients.

Explore further: India's meth addiction grows as criminals tap chemical hub

More information: http://www.epogen.com , http://www.procrit.com .

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

Patient privacy focus of Amgen suit

Jan 09, 2008

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0